Navigation Links
Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
Date:8/12/2008

VANCOUVER, Aug. 12 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has received CE Mark approval to begin marketing the HemoStream(TM) Chronic Dialysis Catheter in Europe.

This CE Mark approval follows Angiotech's announcement in August 2007 that it had received clearance from the U.S. Food and Drug Association (FDA) to begin marketing HemoStream in the United States. In April of the same year, Angiotech entered into an agreement with Rex Medical, LP that granted Angiotech an exclusive license to market and distribute HemoStream worldwide.

"This CE Mark approval is another example of the international acceptance of Angiotech's technologies. With Rex Medical as our worldwide licensing partner, we look forward to expanding HemoStream's availability in Europe as well as in the United States," said Dr. William Hunter, President and CEO of Angiotech.

About the HemoStream Chronic Dialysis Catheter

Incidences of End Stage Renal Disease (ESRD) requiring dialysis are a rapidly growing challenge in healthcare worldwide. When kidneys fail, function of the kidneys can be partially replaced using a process called hemodialysis. This process involves drawing blood out of the body, filtering it through a large machine and then returning filtered blood back to the body. Chronic dialysis catheters, such as HemoStream, are used as long-term vascular access for hemodialysis. HemoStream may also be used as a temporary access while more permanent options mature or become ready for use, such as surgically created AV fistulas.

About Rex Medical, LP

Rex Medical, LP, based in Conshohocken, PA, is a priva
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotech wins before the UK House of Lords
2. Angiotech to Establish Separate Operating and Royalty Businesses
3. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
4. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
5. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
6. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
7. Angiotech appoints Hank McKinnell to its Board of Directors
8. Angiotech to participate in Bank of America Health Care Conference
9. Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO
10. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
11. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... -- AmnioChor Inc., an early stage biotech startup based on ... that the Musculoskeletal Transplant Foundation of Edison ... seed round of development of the proprietary AmnioCept™ product ... AmnioChor,s technology allows cryopreservation of the amniotic membrane ... within those tissues. Amnion is a well-established source of ...
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE MKT: ... results will be released on Thursday, August 13, 2015, ... Time, Pfenex management will host a conference call to ... A press release outlining the financial results and business ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) ...
(Date:7/29/2015)... ... 29, 2015 , ... The third Medical Innovation Impact Index (MI3) Alert considers ... drug/device combinations. The current system received a score of 0 (range -10 to +10) ... (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... 1, 2011 Investor Uprising ( www.investoruprising.com ) has ... guide to the best biotech Exchange Traded Funds (ETFs) ... users of the Website. (Logo: http://photos.prnewswire.com/prnh/20110411/NY80781LOGO-a) ... ongoing biotech bull market, identifying the leading biotech mutual ...
... June 1, 2011 Aaron Mitchell, managing principal at global ... top 25 consultants of 2011 by Consulting Magazine. Mitchell was ... biotech firm over several years and during a major, recent ... one of the top consultants," said Mitchell, who has more ...
... June 1, 2011 Reportlinker.com announces that ... in its catalogue: Osteosarcoma ... to 2017 http://www.reportlinker.com/p0546797/Osteosarcoma-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... Assessment and Market Forecasts to 2017 ...
Cached Biology Technology:Investor Uprising Publishes Free Biotech Investment Report 2Investor Uprising Publishes Free Biotech Investment Report 3Managing Principal at ZS Associates Named One of Consulting Magazine's Top 25 Consultants of 2011 2Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 9Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 10
(Date:7/21/2015)... 21, 2015 Passwords have proven futile ... the recent U.S. Office of Personnel Management breach. ... infosec conundrum, but developers and end-users are concerned ... this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today ... for third party integration. A ...
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... list of 235 planthoppers from Iran is recorded along with ... Iranian Auchenorrhyncha during last 100 years. In addition to the ... transferring one species at family level is proposed. The study ... . Planthoppers are studied relatively little, but are ...
... on Centers for Disease Control and Prevention and other ... 30 years, we recognize the importance of reaching our ... with teachers having to incorporate more and more learning ... leave room for nutrition education in elementary schools? ...
... antibody developed by MassBiologics of the University of Massachusetts ... C virus (HCV) infection undergoing liver transplantation significantly suppressed ... and delayed the time to viral rebound. Results from ... this week at The Liver Meeting, the annual meeting ...
Cached Biology News:Cooking in the classroom to fight childhood obesity 2Experimental drug suppresses rebound of hepatitis C virus in liver transplant patients 2Experimental drug suppresses rebound of hepatitis C virus in liver transplant patients 3
(3-[125I]iodotyrosyl26)Galanin, porcine, 370 kBq, 10 uCi. Category: IODINE LIGANDS....
Homo sapiens postsynaptic protein CRIPT Antigen: Recombinant Protein...
Immunogen: Synthetic peptide based on the sequence: SPSSGPSLTADSMWR Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Biology Products: